3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
32
Phase NA
14
Phase 3
10
Phase 1
7
Phase 1/2
5
Phase 2/3
2
Status
Unknown
4
Recruiting
3
Withdrawn
2
Terminated
2
Completed
2
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Dermatologic
1
Conditions
Skin Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
9
Paclitaxel
8
Gemcitabine
8
Cisplatin
8
Cyclophosphamide
7
Fluorouracil
6
Docetaxel
5
Capecitabine
5
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Vinorelbine
3
Stem Cell Transplantation
3
Radiotherapy
3
Pemetrexed
3
Melphalan
3
Leucovorin
3
Filgrastim
3
Erlotinib Hydrochloride
3
Bone Marrow Transplantation
3
Bevacizumab
3
umbralisib
2
ublituximab
2
pembrolizumab
2
peginterferon alfa-2b
2
fludarabine
2
Whole-Body Irradiation
2
Trastuzumab
2
Transplantation, Homologous
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Terminated
×
Surgical Procedures, Operative
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled
NCT02326285
2018-01-23
NeoIntercal
AIO-Studien-gGmbH
Phase 2/3
Terminated
1 enrolled